Trial Profile
An Open Label, Positron Emission Tomography (PET) Study With [11C]AZ10419369 to Determine Central 5-HT1B Receptor Occupancy of ZOMIG Rapimelt (Zolmitriptan) in Healthy Male Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Zolmitriptan (Primary)
- Indications Cluster headache; Migraine
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 19 Nov 2010 Actual patient number (10) added as reported by ClinicalTrials.gov.
- 18 Oct 2010 Actual end date added to 1 Oct 2010 as reported by ClinicalTrials.gov record.
- 18 Oct 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.